Background and purpose Obesity may be more likely to lead to asthma,
that is, obesity asthma. Children are the age stage of high incidence of
asthma. Obesity asthma may be more refractory in children with asthma,
and is more likely to produce glucocorticoid resistance, which greatly
leads to the risk of severe disease in children with asthma. However,
approaches to combating Obesity Asthma/Childhood Asthma complications
are limited by conditions. Existing evidence shows that chrysophanol has
antibacterial and anti-inflammatory, fat reduction, anticough, promoting
gastrointestinal functional homeostasis and immune regulation.
Experimental methods Through systematic pharmacological and
bioinformatics analysis, we evaluated the physical and chemical
properties and biological activities of chrysophanol, and further
analyzed its binding activities, targets, biological functions and
mechanisms. Key results It was found that chrysophanol can play the
ideal physical and chemical properties and biological activities. The
PPI network screened 144 common targets of drugs and diseases, and 15
hub targets were obtained. Then, the top 10 hub targets were identified,
namely EGFR, HSP90AA1, ESR1, HIF1A, STAT3, SRC, PTGS2, MTOR, MMP9,
PIK3CA, and verified in the protein-ligand blind docking. Enrichment
analysis showed that chrysophanol may be involved in inflammation
regulation, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling
pathway, Neutrophil extracellular trap formation,and so on. Conclusions
and implications Our fingdings indicate that chrysophanol can reduce
airway inflammation and remodeling through multi-pathway and
multi-target, and provide evidence for the application of chrysophanol
in Obesity Asthma/Childhood Asthma comorbidities. The predicted results
will be strictly verified by experiments.